Home › Biogen buys UK-based neuropathic pain drug developer for up to $675M
 

Keywords :   


Biogen buys UK-based neuropathic pain drug developer for up to $675M

2015-01-12 06:43:14| Biotech - Topix.net

Biogen Idec is getting into the neuropathic pain treatment field with the acquisition of a U.K. drug developer for up to $675 million. The Cambridge biotech firm , known best for its drugs for multiple sclerosis, announced the acquisition of Convergence Pharmaceuticals on the first weekend of the J.P. Morgan Healthcare conference in San Francisco.

Tags: drug pain developer buys

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Eastern North Pacific Tropical Weather Outlook
05.07Tubi and Pluto lead U.S. surge in free streaming
05.07Tubi free streaming service launches in the UK
05.07Simplestream reveals preferred technology partnership with Freely
05.07TikTok launches on whaleOS 3-powered TVs
05.07Hurricane Beryl Graphics
05.07Hurricane Beryl Forecast Discussion Number 28
05.07Tropical Depression Aletta Graphics
More »